Across TCGA pan-cancer cohorts, SLC36A3 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of SLC36A3’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where SLC36A3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC36A3 is over-expressed in tumor.

PAAD and KIRC are the cancer types where SLC36A3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC36A3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PAAD	Male	All	+0.025	.037	2	view →
KIRC	All	All	+0.004	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: SLC36A3 RNA expression & survival · all SLC36A3 data types